Citation

Adelufosi AO, Abayomi O, Ojo TMF. Cochrane Database Syst. Rev. 2013; 2013(4).

Copyright

(Copyright © 2013, The Cochrane Collaboration, Publisher John Wiley and Sons)

DOI

10.1002/14651858.CD010501

PMID

unavailable

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the effects of pyridoxal 5 phosphate (pyridoxine, pyridoxal phosphate, tardoxal) for treating neuroleptic-induced tardive dyskinesia in individuals of any age group with schizophrenia and other psychotic disorders. © 2013 The Cochrane Collaboration.

Language: en

Keywords

human; suicide; systematic review; schizophrenia; psychosis; mortality; risk assessment; neuroleptic agent; priority journal; hallucination; age distribution; delusion; placebo; clinical protocol; drug efficacy; tardive dyskinesia; drug effect; sensitivity analysis; Article; outcome assessment; treatment duration; randomized controlled trial (topic); neuroleptic induced disease; pyridoxal 5 phosphate